Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anisodine is a tropane alkaloid naturally occurring in plants of the *Anisodus* genus, such as *Anisodus tanguticus*. It functions as a muscarinic acetylcholine receptor antagonist, chemically related to scopolamine but containing an additional hydroxyl group. In China, anisodine is primarily utilized for its ability to improve microcirculation and its anticholinergic effects. It is indicated for the treatment of migraine, acute circulatory failure (shock), and organophosphate poisoning. In the field of ophthalmology, it is specifically used to treat conditions such as ophthalmoplegia (paralytic strabismus) and ischemic optic neuropathy, often administered via peribulbar or retrobulbar injection to enhance local blood flow and nerve recovery. The First Affiliated Hospital of Harbin Medical University has been a key institution in the clinical development and application of anisodine for ocular nerve paralysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anisodine.